Samaritan Pharma Retains The Investor Relations Group of New York
Samaritan Pharma Retains The Investor Relations Group of New York
MSN MoneyCentral - Samaritan has partnered its Phase II infectious disease drug SP-01A, an oral HIV viral-entry inhibitor, to Pharmaplaz, Ireland. Additionally, its Alzheimer’s drug Caprospinol, with the potential to restore memory loss in Alzheimer’s disease patients
A troubling abundance of care
Newark Star-Ledger - So did gastroenterologists, infectious disease specialists, neurologists, internists and a cardiologist, according to a 22-page Medicare summary. Her daughter said she felt helpless as the tests and consultations snowballed. Glas, a former nurse
Colorado BioScience Association Announces Winners Of Its 2007 Awards
dBusinessNews.com - Inviragen and its collaborators are developing novel vaccines to protect against worldwide infectious disease threats, such as dengue fever, West Nile disease, and plague/smallpox. In 2006, Inviragen opened its office and laboratory facilities in